Cimzia Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Cimzia market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historical period can be attributed to several factors, including the rising prevalence of autoimmune diseases, increased awareness of biological therapies, a surge in healthcare expenditure, greater adoption of self-injectable biologics, and expanded biologic drug manufacturing capacity.

Looking ahead, the growth in the forecast period is expected to be driven by several key factors: rising demand for targeted biologics, increasing patient preference for self-administration devices, heightened biosimilar competition, growing government healthcare funding, and a stronger focus on personalized medicine. Key trends in the forecast period include a shift towards patient-centric drug delivery solutions, the adoption of digital health tools for disease management, the growing use of real-world evidence in drug development, the expansion of telemedicine and home care solutions, and the integration of AI in clinical trials.

The growing prevalence of rheumatoid arthritis (RA) is expected to drive the expansion of the cimzia market. RA is a chronic autoimmune disorder where the immune system attacks the body's joint tissues, causing inflammation, pain, and swelling. The rise in RA cases can be linked to an aging population, increasing genetic predisposition, environmental factors such as smoking and pollution, and greater awareness and diagnosis of the condition. Cimzia plays a crucial role in managing RA by providing targeted therapy to reduce inflammation, relieve symptoms, improve patient well-being, and aid in better disease management. For example, in May 2022, the Pain Relief Foundation, a UK-based charity, reported that arthritis and musculoskeletal conditions affect over 17 million people in the UK, leading to 30 million lost working days annually, while chronic pain affects up to 62% of those over 75. Additionally, in February 2024, the Centers for Disease Control and Prevention (CDC) reported that the age-adjusted prevalence of diagnosed arthritis in adults aged 18 and older was 18.9% in 2022, with women (21.5%) more likely to have arthritis than men (16.1%). Therefore, the increasing prevalence of rheumatoid arthritis is driving the growth of the cimzia market.

A key trend in the cimzia market is the development of innovative treatments, such as autoimmune therapy solutions, to address unmet needs in autoimmune disease management, particularly for patients with non-radiographic axial spondyloarthritis (nr-axSpA). Autoimmune therapy solutions aim to restore immune balance and tolerance, often using targeted immunotherapies and cellular therapies. For example, in July 2024, UCB, a Belgium-based biopharmaceutical company, announced the expansion of Cimzia (certolizumab pegol) as a treatment for patients with nr-axSpA. This expansion provides an innovative option for patients who have not yet shown radiographic evidence of the disease but still experience symptoms. Cimzia is the first biologic to receive FDA approval for nr-axSpA, establishing its unique position in autoimmune treatment. This approval offers an important alternative to traditional therapies, improving symptom management and quality of life for patients.

In February 2022, Biogen Inc., a US-based biotechnology company, entered into a licensing agreement with Xbrane Biopharma, a Sweden-based biopharmaceutical company, to develop, manufacture, and commercialize Xcimzane, a biosimilar to Cimzia. This partnership aims to provide more affordable treatment options for patients with rheumatoid arthritis and other conditions, promoting better access to care and contributing to healthcare savings through the availability of a cost-effective alternative to the original drug.

Key player operating in the cimzia market is UCB SA.

North America was the largest region in the cimzia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cimzia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cimzia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cimzia (certolizumab pegol) is a PEGylated monoclonal antibody that targets tumor necrosis factor (TNF), used to reduce inflammation and prevent immune system-related damage in certain autoimmune diseases. It is used in treating moderate to severe rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.

The primary types of cimzia are biologics and biosimilars, designed to address the needs of both adult and pediatric patients. Cimzia is distributed through various channels, including hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. Its applications extend to treating conditions such as Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, active psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis.

The cimzia market research report is one of a series of new reports that provides cimzia market statistics, including cimzia industry global market size, regional shares, competitors with a cimzia market share, detailed cimzia market segments, market trends and opportunities, and any further data you may need to thrive in the cimzia industry. This cimzia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cimzia market consists of sales of injectable formulations, pre-filled syringes, auto-injectors, and IV infusions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.